We conducted a retrospective review of the clinical features and outcome of adenovirus infection in 572 consecutive patients transplanted in a single centre over a 10 year period. One hundred patients (17%) had a total of 105 episodes of adenovirus infection diagnosed at a median of 18 days post transplant (range 2-150 days). The incidence was higher in children than adults (21% vs 9%, P Ͻ 0.001) and in unrelated donor vs matched sibling donor transplants (26% vs 9%, P Ͻ 0.001). Diarrhoea and fever were the most common presenting features. Reflecting these symptoms, the most common site of isolation was the stool. Serotypes 1, 2 and 7 were the most frequently seen (total of 41/68 or 60% of evaluable cases). In six patients (6%) adenovirus infection was the direct cause of death occurring at a median of 72 days post transplant (range 18-365 days). Five of these six patients had pulmonary involvement and four had associated graft-versus-host disease (GVHD). Three further patients were considered to have severe adenoviral disease (total incidence 9%). Isolation of virus from multiple sites correlated with a poor outcome (P Ͻ 0.001). Comorbid viral infection was common in this group with 50% of all patients having other viruses isolated (predominantly polyoma virus and cytomegalovirus). We conclude that adenovirus is commonly isolated after bone marrow transplant and is a cause of significant morbidity but was a rare cause of mortality (6/572 = 1%) in our patient group as a whole. The relative infrequency of severe infection will make it difficult for the transplant physician to decide which patients should receive experimental antiviral drugs such as ribavirin and cidofovir or immunomodulatory therapy with donor white cell infusions. Bone Marrow Transplantation (2000) 26, 1333-1338. Keywords: adenovirus; bone marrow transplantation; diarrhoea; pneumonitis Viral infections are a common cause of morbidity and mortality after bone marrow transplantation. Severe, life-threat-
ening viral infections appear to be more common after unrelated donor bone marrow transplants (UD-BMT). 1 Risk factors for severe viral infection include graft-versus-host disease, steroid and antilymphocyte globulin therapy, prior exposure of either donor or recipient to relevant viruses, contact with infected persons and infection with fungi and other viruses. The most common viral infections seen after BMT include cytomegalovirus, herpes simplex and varicella zoster viruses. 2 Herpes zoster and herpes simplex generally respond well to aciclovir and in the last 10 years major progress has been made in the early diagnosis and prophylaxis of CMV infection, so that now it is a much less common cause of death. 3 Attention is now being also focussed on community-acquired respiratory viruses 4 and other viruses including adenovirus.
Adenovirus is a nonenveloped double-stranded DNA virus that causes both active and latent infection. Primary infection usually occurs in early life with a symptomatic or asymptomatic infection and lifelong persistence of specific antibody. In normal hosts infection usually causes respiratory illnesses ranging from pharyngitis to pneumonia, particularly with serotypes 1, 2, 5 and 6. Adenovirus enteritis is also common in normal children (mainly with the non-cultivable serotyes 40 and 41). There are 47 human serotypes but less than 40% of these have been implicated in human disease. 2 The serotypes are classified into six groups (A-F) on the basis of antigenic properties and DNA homology. Adenovirus is isolated in 5-21% of BMT patients [5] [6] [7] but its significance is often uncertain. It may be more common in children than adults. Rarely, it causes disseminated infection with haematuria, hepatic necrosis and pulmonary involvement; this is commonly fatal. More commonly it is isolated from the stool of patients with diarrhoea and fever (some of whom may have other causes for diarrhoea such as GVHD). In some reports, GVHD and its treatment predict for the development and severity of infection. Treatment is generally supportive as there is no proven therapy for this virus although there are anecdotal reports of successful therapy with ribavirin, 8 ganciclovir 9 and cidofovir. 10 In this retrospective study, we report 100 BMT patients with adenovirus infection, describe their clinical features and outcome and analyse the factors that predict for severe infection.
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Patients and methods
Patient population and identification
The Bristol BMT unit is a tertiary referral centre that specializes in UD-BMT, particularly in children. From September 1987 to August 1998, 572 stem cell transplants (313 UD, 161 sibling allografts and 98 autologous) were performed in 391 children and 181 adults. The age breakdown of these patients was as follows: 0-9 years, 263; 10-19 years, 173; 20-29 years, 51; and 30 years or more, 85 patients (median age 10.8 years). Three hundred and fortysix were male and 216 female. Acute leukaemia was the most common diagnosis (340 cases = 59%).
We conducted a retrospective review of the case records, the BMT database and the computerised and printed database of the Virology Department of the Public Health Laboratory Service for patients with adenovirus infection. One hundred patients (17%) were found to have 105 episodes of infection (Table 1 ). In addition we collected demographic, epidemiological and transplant-related data from patients identified to have adenovirus infection. 
Conditioning and GVHD prophylaxis
This has been described previously in detail. 11 The standard conditioning regimen, used for the majority of patients with an unrelated donor, consisted of intravenous CAMPATH 1G (10 mg twice a day) on days −9 to −5, cyclophosphamide (60 mg/kg) on days −6 and −5 and total body irradiation (TBI) (14.4 Gy) given in eight fractions on days −3 to day 0.
11 Some patients who had previously undergone TBI or other extensive radiotherapy had an alternative regimen consisting of CAMPATH, cyclophosphamide (200 mg/kg) and busulphan (16 mg/kg).
Unrelated donor marrows were generally incubated with CAMPATH antibodies. Sibling allografts were in general conditioned with the same agents but were given T cell replete marrow. With regard to autograft patients, those with myeloma received intravenous melphalan, those with acute myeloid leukaemia busulphan and cyclophosphamide and patients with lymphoma received conditioning therapy with BCNU, etoposide, cytosine arabinoside and melphalan (BEAM). Cyclosporin A (CsA) was given to allograft patients from day −1, then slowly tapered at 6 months in the absence of GVHD. Three doses of intravenous methotrexate (15 mg/m 2 on day 1 and 10 mg/m 2 on days 3 and 6) were also given.
Isolation and identification of adenoviruses
Clinical samples (which included nose and throat swabs, bronchoalveolar lavage specimens and faeces) were inoculated into a range of cell cultures including human embryo kidney (HEK), HEp2 and Graham 293 (adenovirus transformed HEK). Cultures were examined on alternate days for viral cytopathic effect (CPE). Cultures showing the characteristic CPE were harvested for serotyping. Serotyping was usually performed by neutralisation in Hep2 cells with polyclonal antisera and sometimes by immunofluorescence with monclonal antisera. If a serotype was not determined at the time of diagnosis, retrospective serotyping was performed if stored samples were available. Virus was also demonstrated in faeces by electron microscopy. All patients with diarrhoea had faeces sent for viral studies but there was no surveillance testing of asymptomatic patients.
Definitions
Severe adenoviral infection was said to exist when adenovirus was the major cause of death or when there were severe complications of infection such as pulmonary or hepatic involvement (with no other evident cause) or when viral infection appeared to contribute to graft failure. Fever was said to be present if a temperature of 38°C occurred within 24 h of viral identification. Diarrhoea was said to be due to adenovirus if it occurred within 48 h of adenovirus isolation and no other cause was apparent. Liver function was considered to be abnormal if the bilirubin was Ͼ40 mol/l at the time of viral isolation.
Risk status refers to predictors of overall transplant outcome. The following features were considered high risk: advanced phase disease (not in remission, CR3, accelerated phase chronic myeloid leukaemia) and HLA mismatched allografts (Ͼ1 antigen mismatched unrelated donor transplant in a child, any mismatch in an adult 12 and haploidentical family member grafts). Infections were defined as early if occurring in the first 100 days, and as late thereafter. Five patients had more than one episode of infection. In all these cases the serotype was different in the two episodes. Acute GVHD was graded as stages I to IV using standard criteria 13 and chronic GVHD was assessed as being absent, limited or extensive.
14 The day of engraftment was defined as the first of 3 consecutive days on which the ANC remained at 0.5 × 10 9 /l or more.
Supportive care
This has previously been described in detail. 3 From 1992, all patients were transplanted in positive pressure single rooms with air filtration by EU8-grade filters, and remained in protective isolation from day 0 until engraftment. Patients were free to leave the unit during conditioning. All patients received 'clean' diets which excluded fresh fruit and vegetables and tap water from day −3 until 30 days after discharge from isolation. Patients who were readmitted to the unit for management of complications were housed in single rooms without air filtration. Intravenous access was achieved by a double lumen tunnelled central venous catheter.
Ciprofloxacin, cotrimoxazole, itraconazole and phenoxymethylpenicillin were given prophylactically. Patients at low risk of CMV disease (both patient and donor seronegative) received low-dose oral aciclovir (400 mg three times a day in an adult) from day −4 and CMV seronegative blood products. Patients at high risk of CMV disease (patient, donor, or both seropositive) received highdose aciclovir (500 mg/m 2 three times a day intravenously) from day −4 to day +30, thereafter oral aciclovir (400 mg three times a day), and normal pooled human immunoglobulin (200 mg/kg) every 3 weeks, commencing on day −1. CMV prophylaxis was given routinely for 6 months, but continued if there was severe chronic GVHD. If there was evidence of CMV reactivation (viraemia without evidence of disease) in the blood or bronchoalveolar lavage, ganciclovir was administered for at least 2 weeks at 5 mg/kg twice a day. CMV disease (pneumonitis or other organ disease or pancytopenia, fever and viraemia) was treated with ganciclovir plus intravenous immunoglobulin.
Febrile neutropenia (defined as pyrexia of 38°C or more on two occasions within 1 h, or by a single episode of pyrexia of 38.5°C) in a patient with ANC Ͻ 1 × 10 9 /l, was treated with broad spectrum intravenous antibiotics, with the addition of intravenous amphotericin at 72 h for patients with refractory fever.
Diarrhoeal stools were cultured for Salmonella, Shigella, Campylobacter and E. coli O157. Liquid stool samples were also analysed for Clostridium difficile toxin (tissue culture), Cryptosporidium and for viruses (electron microscopy and culture, more recently ELISA for rotavirus and PCR for small round structured viruses).
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Statistics
All data were analysed on 1 December 1998. We conducted a univariate analysis of risk factors for death from adenovirus infection. The risk factors we examined included: gender, age, risk status, presence of GVHD, steroid therapy, other viral infection, time of viral isolation, adenovirus serotype. In addition the presence of fever, pneumonitis, ventilation, liver dysfunction, neutropenia were considered. Fisher's exact test was used to compare proportions and Mann-Whitney U-tests to compare continuous variables; two-tailed tests were used throughout.
Results
Patient characteristics
Infected patients were predominantly paediatric (83% Ͻ18 years) and males outnumbered females ( Table 1 ). The incidence of adenoviral infection in children was 21% and in adults 9% (P Ͻ 0.001). Seventy-nine of 313 unrelated donor BMT patients (26%) developed adenovirus infection compared to 15 of 161 matched sibling transplant patients (9%) (P Ͻ 0.001). Three-quarters of all patients had leukaemia (mainly ALL) and over half were classified as high risk transplants. Over two-thirds had early stage disease and three-quarters were T cell-depleted unrelated donor transplants reflecting the unit's specialist interests. The median time to diagnosis was approximately 18 days post BMT.
Clinical presentations and manifestations
Seventy-four patients had symptoms of diarrhoea and nearly half had fever. Ten patients had macroscopic haematuria occurring at a median of 18 days post BMT (range −2 to +150). Four required catheterisation and three continuous bladder irrigation. None of these 10 patients had adenovirus isolated from their urine and six of them had polyomavirus detected in their urine. Four additional patients who had adenovirus isolated from their urine had no haematuria. Seventeen patients had a bilirubin level Ͼ40 mol/l at the time of viral diagnosis; nine of these 17 had an AST Ͼ100 units/l. Nine patients developed a bilirubin Ͼ100 mol/l and in three this rose to above 200 mol/l. Three of these nine patients (with a bilirubin Ͼ100 mol/l) had concurrent severe visceral GVHD. However, in only one patient were characteristic intranuclear inclusions found in hepatocytes. 15 Seven patients developed pneumonitis 26 days to 4 years post BMT (median 7 months), but four had other relevant viral infections (2 CMV, 1 RSV and 1 influenza A). All had abnormal radiological findings but there was no consistent abnormality on chest X-ray. All had tachypnoea and an increased oxygen requirement; one patient required mechanical ventilation. Two of the seven had adenovirus isolated from bronchoalveolar lavage specimens and one from a nasopharyngeal aspirate. None of the seven patients had lung biopsies or post-mortem examinations.
Four patients had possible CNS involvement. Two patients became profoundly confused and two had seizures with no other apparent cause. Only one of these four patients had adenovirus isolated from the CSF.
Identification
Faeces was overwhelmingly the most common site of first isolation (83%), with nose and throat being second most common (Table 2) . Eleven patients had adenovirus isolated from multiple sites. Electron microscopy provided a rapid diagnosis in two-thirds and in 10% it was the only method able to detect virus.
Serotyping
Eleven of the 105 cases (10%) of adenovirus infection were diagnosed by electron microscopy only and therefore could not be serotyped. Of the remaining 94 cases, 68 (74%) had a serotype assigned (Table 3) . Of the remaining 26 cases, there were a variety of reasons for the inability to serotype including age (Ͼ8 years) of stored samples, some stored specimens being of poor quality and the known limited growth of certain non-cultivable serotypes. The most com- a Four of these patients also had adenovirus detected in nose and throat secretions and four had adenovirus in their urine. One patient also had adenovirus detected in the CSF, ascitic fluid and in a gastric biopsy specimen. CMV = cytomegalovirus; HSV = herpes simplex virus; RSV = respiratory syncytial virus; EBV = Epstein-Barr virus; SSRV = small round structured virus. In 94 cases, the virus was isolated in cell culture and the reasons for the inability to serotype 26 cases is stated in results.
mon serotypes found were 1, 2 and 7. Only three of the six patients with lethal adenovirus infection were assigned serotypes; these were 1, 5 and 32. 15 In general it was not possible to ascribe certain disease presentations to specific serotypes. Diarrhoea, a common but non-specific symptom, occurred in 74 cases and a serotype was assigned in 47 of these. The most prevalent serotypes in this group were 1 and 7 (12 and 14 cases, respectively) but the distribution of serotypes in this symptom group was not significantly different from the entire group of patients together. In the nine patients with severe jaundice (bilirubin Ͼ100), the serotype distribution in seven evaluable cases was 2 (two), 3 (two) and 1, 4 and 7 each in one case.
Risk factors for infection
There was no clear association between GVHD and adenoviral infection. Thirty-eight of 102 evaluable patient episodes were associated with GVHD, with 34 of them being grade II-IV GVHD or grade I GVHD requiring systemic steroid therapy. In the 79 patients who had UD-BMT, 21 had grade II-IV GVHD and 10 grade I GVHD. It was not possible to directly compare the incidence of GVHD with that in patients not infected with adenovirus but the incidence of GVHD in the group with adenovirus infection was not significantly different to that seen in our previously published series of paediatric unrelated donor recipients. 12 Late infection was seen in 20 cases and 11 of them had acute and/or chronic GVHD (55%) but the numbers are insufficient to ascertain if there is a statistical association.
Sixty other viruses were isolated from 50 of these patients (50%). Eight of these infections were life-threatening. Twelve patients had more than one other viral infection, one patient had four other viruses isolated.
Associated syndromes
Four patients developed thrombotic thrombocytopenic purpura; graft failure (primary and secondary) was seen in eight patients. All patients with graft failure have subsequently died but in only one case was adenovirus the only possible cause. Three additional patients had delayed engraftment that could in part have been attributable to adenovirus infection. Twelve patients had concurrent proven or probable fungal infection; eight of these were fatal.
Survival, cause of death and predictors of severe infection
Forty-three of the 100 patients survive at a median followup of 3 years. Adenovirus infection was the cause of death in six patients 18 days to 12 months (median 72 days) post-BMT. Five of these six patients had pulmonary involvement and four had grade II-IV GVHD. Three additional patients had severe disease (not directly the cause of death) as defined in Materials and methods. Four of the six patients who died had adenovirus isolated from multiple sites (P Ͻ 0.001).
Of the remaining patients who died, four died due to other viral infections. The other major causes of death were relapse (21 patients) and fungal infection (8 patients) . A number of potential variables were examined with a univariate analysis to determine if they were associated with severe disease (Table 4) . A high risk transplant was associated with severe disease (P = 0.165, not significant) and all patients with severe disease were recipients of unrelated donor transplants (P = 0.11). Four of the five patients with two episodes of adenovirus died (none directly due to adenovirus), but this is not statistically significant.
Discussion
Adenovirus infections are a recognised cause of morbidity and mortality in bone marrow transplant recipients. The Table 4 Analysis of factors potentially influencing disease severity High risk is defined in Methods.
Bone Marrow Transplantation incidence varies from 5% 5 to 21% 7 depending on the detection methods used and the population being studied. Possible methods of infection include primary respiratory, faecal-oral transmission or reactivation of latent virus. Severe involvement of the liver, bowel, bladder, 16 kidney, lung and brain 17 have been described. However, many BMT patients develop adenovirus infections without it significantly affecting their clinical course.
In our study we report an 17% incidence of infection and a 6% case fatality rate which is higher than the 1-6% incidence in the four major series reported. [5] [6] [7] 18, 19 Severe disease was documented in 9%. Similar to the Milwaukee group, 7 our patients comprise a large number of unrelated donor recipients. This group may have a higher incidence of infection (26% in our series), as may recipients of haploidentical transplants (F Aversa, personal communication).
The largest previous study of adenovirus infection in BMT patients revealed a 21% incidence in 201 patients with a higher incidence in children than adults. 7 Adenovirus type 35 was the most common serotype found, very different to the predominance of serotypes 1, 2 and 7 seen in our patients. One-third of these patients with infection had definite or probable adenovirus disease, considerably higher than in our series. Risk factors for the development of disease were isolation of the virus from more than one site (confirmed by our study) and the presence of moderate to severe acute GVHD. The most common site of isolation was the stool.
As well as causing lethal infection, adenovirus infection may cause diagnostic confusion, particularly by mimicking some of the symptoms of gastrointestinal GVHD. Diarrhoea is the most common of these. Viral infection is an important cause of diarrhoea post BMT. One study of 94 patients (two-thirds allogeneic, one-third autologous BMT) that performed twice weekly surveillance of stools for the first 3 months found a 20% incidence of viral gastroenteritis with half of these being due to adenovirus. 20 The median time to first isolation was 46 days, no particular serotype was found to be more common and there was a significant association with acute GVHD. In another study, 31 (40%) of 78 patients with diarrhoea were found to be infected with an enteric pathogen; 12 of 31 infected patients (39%) were shown to have adenovirus. 21 The relationship between adenovirus infection and GVHD is uncertain. The two may coexist, viral infection may be a trigger for GVHD and the immunosuppression associated with GVHD and its therapy may make a viral infection more likely. Some studies find an association 5, 18 but the incidence of acute GVHD in our patient group was similar to that in unrelated donor transplant patients without adenovirus infection. 12 About 10% of our patients developed macroscopic haematuria. However the link with adenovirus is far from certain. The association between haemorrhagic cystitis and viruses is not clear because some cystitis may be due to cyclophosphamide and viruses are commonly found in the urine of asymptomatic individuals. Adenovirus, particularly serotype 11, 18 is uncommonly associated with haemorrhagic cystitis in children. Its tendency to spontaneously resolve makes assessments of the impact of experimental antiviral therapy difficult. There are anecdotal reports of successful therapy with ribavirin 8 and ganciclovir, 9 but patient numbers were small. In summary, adenovirus infection is common after stem cell transplant, occurring in up to a fifth of all patients. Mortality directly attributable to virus occurs in up to 5-10%, but the virus is also the cause of considerable morbidity and diagnostic confusion. Even in this large study the relatively small number of patients with severe adenoviral disease made it difficult to analyse which factors determine the severity of viral infection, but there were trends towards recipients of unrelated donor marrow and high risk transplants as a whole being more at risk. Isolation of virus from multiple sites did correlate with death from adenovirus; this would seem to be the logical group to target with experimental antiviral therapy. 10 There is no convincing evidence of efficacy for any particular antiviral drug and it may be that virus-specific T cells (in a manner analogous to CMV) are worth exploring as a therapeutic option. 22 
